The obesity market grew up today. When the Medicare GLP 1 Bridge goes live, it marks the shift from the era of scarcity to the era of access. The first phase of the GLP 1 story was about demand outrunning supply—injectable shortages, compounding pharmacies filling the gap, cash pay patients paying whatever it took. The Pharma Letter captures where we are now: a “more practical second phase” defined by access and durability rather than the injectable demand surge that defined the first wave.
The Bridge answers the access question for roughly 60 million Medicare beneficiaries, putting Foundayo, Zepbound, and both forms of Wegovy within reach at $50 a month. That is a structural expansion of the market. And it lands the same week Lilly is filing Foundayo for type 2 diabetes and preparing retatrutide for a 2027 launch. The competitive terrain now runs across three axes: efficacy (retatrutide’s 28.3% at the top), convenience (oral Foundayo and oral Wegovy), and access (the Bridge). Whoever wins depends on which axis matters most to which patient.
Separately, the thyroid eye disease market went from a monopoly to a three way race in the span of two business days. Roche received FDA acceptance and priority review for Enspryng in TED, one day after Viridian’s Lumvoa was approved. Amgen’s Tepezza had the market to itself for six years. Now it faces two challengers simultaneously. And Abivax clawed back a 44% crash after new data showed its UC drug’s cancer signal was in line with what is normally seen in UC patients.
The Medicare GLP 1 Bridge Launches Today
This is the most consequential policy event in the obesity market since the drugs launched. Starting today, Medicare Part D beneficiaries with obesity (BMI 30 or above) or overweight with comorbidities (BMI 27 or above) can access GLP 1 therapies at a $50 monthly copay.
What Is Covered
Both Lilly products and both Novo products are available from day one:
Lilly: Foundayo (oral, approximately 12% weight loss, no food or water restrictions) and Zepbound (injectable, approximately 22% weight loss, once weekly).
Novo Nordisk: Oral Wegovy (approximately 15% weight loss) and injectable Wegovy (approximately 15 to 17% weight loss, once weekly).
The level playing field matters. Earlier this year, Novo secured Medicare coverage for oral Wegovy ahead of Lilly, creating a first mover advantage in the Medicare population. Lilly’s deal to restore Zepbound coverage and include Foundayo erased that advantage. Both companies start today on equal footing.
Why This Is a Different Kind of Market Expansion
Medicare has historically been barred from covering weight loss drugs. The Bridge works around that through the framework negotiated as part of the MFN pricing deals earlier this year. The trade was explicit: pharmaceutical companies accepted lower pricing in exchange for broader access. Today is where that trade begins to produce enrollment data.
For approximately 60 million Medicare beneficiaries, GLP 1 therapy has been largely out of reach. List prices of $500 to $1,000 per month made these drugs unaffordable for most seniors on fixed incomes. At $50 per month—comparable to a typical generic drug copay—the financial barrier effectively disappears.
The population that gains access today is different from the commercial and employer covered populations that have driven GLP 1 adoption so far. Medicare beneficiaries are older, have more comorbidities (diabetes, cardiovascular disease, osteoarthritis, sleep apnea), and in many cases have been living with untreated obesity for decades because no affordable pharmacological option existed. The clinical impact of treating this population could be substantial: weight loss in seniors reduces cardiovascular events, improves mobility, manages diabetes, and may reduce falls and hospitalizations.
The Competitive Dynamics from Here
The Pharma Letter’s framing of a “more practical second phase” captures the shift precisely. The first phase of the GLP 1 story was about which drug produced the most weight loss. Retatrutide at 28.3%. Zepbound at 22%. Wegovy at 15 to 17%. Foundayo at 12%. The efficacy hierarchy was the story.
The second phase adds two more dimensions. Convenience: oral Foundayo (no food restrictions) versus oral Wegovy (requires fasting). For Medicare beneficiaries managing multiple medications and complex daily routines, dosing convenience is not trivial—it directly affects adherence and long term outcomes. Access: the Bridge creates a level playing field on cost, shifting the competition from “which drug can my patient afford?” to “which drug is right for my patient?”
The three axis framework—efficacy, convenience, access—means there is no single winner. Different patients will land on different products. The patient who wants maximum weight loss and is comfortable with injections gravitates toward Zepbound (or retatrutide when it launches). The patient who prefers pills and values simplicity gravitates toward Foundayo. The patient who is already on Novo products and is satisfied stays on Wegovy. The Bridge expands the market without crowning a champion.
Our Pro brief details the Bridge program structure, models enrollment expectations, and analyzes how the competitive dynamics between Lilly and Novo will play out in the Medicare population. [Details below.]
The Thyroid Eye Disease Race Adds a Third Player in Two Days
What Happened: Roche announced that the FDA accepted and granted priority review to a supplemental BLA for Enspryng (satralizumab) in thyroid eye disease. This arrived one business day after Viridian’s Lumvoa (veligrotug) was approved for the same condition.
From Monopoly to Three Way Competition
Amgen’s Tepezza launched in 2020 as the first FDA approved targeted therapy for TED, a condition where autoimmune antibodies cause inflammation, swelling, and bulging behind the eyes that can threaten vision. Tepezza had the market essentially to itself for six years. In the span of two business days, it now faces two challengers through two different mechanisms.
Lumvoa (Viridian, approved Friday): An anti IGF 1R antibody that targets the same receptor as Tepezza but reportedly with a shorter infusion course. The convenience advantage is the competitive wedge—patients with active TED want resolution as quickly as possible, and a shorter treatment course matters.
Enspryng (Roche, priority review accepted): An IL 6 receptor antibody already approved for neuromyelitis optica spectrum disorder. A TED indication would open a new market for the drug through a different mechanism than either Tepezza or Lumvoa. By targeting IL 6 rather than IGF 1R, Enspryng could offer a differentiated safety profile—important because hearing related adverse events have been a concern with the IGF 1R class.
Three drugs, two mechanisms, one market that until last Friday had a single player. For patients with a disfiguring, under treated disease, competition should expand the total treated population by giving physicians more options to match to individual patient profiles. Some patients may respond better to IGF 1R inhibition. Others may respond better to IL 6 blockade. Having both mechanisms available is genuinely good clinical news.
For Amgen, the loss of TED market exclusivity is significant. Tepezza has been a meaningful revenue contributor. Two competitors arriving within days of each other accelerates the market share pressure that Amgen had been able to defer for years. The company is simultaneously navigating the Tavneos regulatory crisis (CHMP revocation recommendation, FDA voluntary removal request). It is not a great month to be in Amgen’s competitive strategy group.
Abivax Recovers 40% as Cancer Signal Fades
What Happened: Abivax shares climbed roughly 40% to 116.5 euros ($133) on Tuesday after new data on its lead ulcerative colitis drug obefazimod eased the safety concerns that had cratered the stock in early June.
The Full Story
Obefazimod crashed about 44% on June 2 when a dataset showed cancer cases among patients on the highest dose. The safety signal was severe enough to trigger a selloff that wiped billions in market value. The market feared that the cancer cases were drug related, which would have been potentially fatal for the program.
The additional data, released late Monday, showed malignancy rates in line with what is normally seen in UC patients. Ulcerative colitis patients have an elevated baseline cancer risk (particularly colorectal cancer) due to chronic inflammation. The data suggest the cancer cases observed in the trial were consistent with the disease’s natural history rather than a drug effect.
Abivax also reported that more than 37% of patients who did not respond initially achieved clinical remission on a 50 mg dose after approximately 10 months. This delayed responder data is clinically meaningful: it means patients who do not respond to obefazimod in the first weeks or months may still benefit if they stay on therapy long enough for the drug’s mechanism to take full effect.
The company remains on track to submit its U.S. NDA in Q4 2026. Analysts have called obefazimod a potential best in class UC treatment. The stock has gained nearly 1,700% since 2025. With a market cap around 8 billion euros and a differentiated oral UC drug approaching filing, Abivax is widely considered one of the most likely takeover targets in European biotech. Every major immunology player—AbbVie, J&J, Lilly, Merck, Roche—has reason to be interested. The question is whether a buyer moves before or after the NDA is submitted.
AstraZeneca Hits Phase 3 in Hypophosphatasia
What Happened: AstraZeneca reported positive Phase 3 data for efzimfotase alfa, an investigational enzyme replacement therapy, showing improved bone health in treatment naive children with hypophosphatasia, a rare inherited metabolic disease.
Why This Matters: Hypophosphatasia is caused by deficient activity of the tissue nonspecific alkaline phosphatase enzyme, leading to defective bone mineralization, skeletal abnormalities, and in severe cases, life threatening complications in infancy. Treatment options are limited. The positive Phase 3 data strengthen AstraZeneca’s rare disease portfolio, built substantially on the Alexion acquisition, and position efzimfotase as a potential next generation option in a condition where existing therapies leave significant unmet need.
For AstraZeneca, which has been expanding aggressively across oncology (Enhertu, Datroway, Truqap, Nuvalent via GSK), cardiovascular (Baxfendy), and now rare disease, the hypophosphatasia data add another growth driver to a pipeline that is producing results across multiple therapeutic areas simultaneously.
BioCryst Exits Internal Discovery
What Happened: BioCryst is winding down its internal drug discovery programs and will close its Discovery Center of Excellence in Birmingham, Alabama, by the end of 2026, shifting toward externally sourced rare disease assets.
Why This Matters: The move reflects a pattern that has defined the industry throughout 2026: companies narrowing internal research in favor of licensing and acquiring later stage assets. Biogen announced the same pivot three weeks ago with “the new Biogen.” Lilly built its entire 2026 pipeline through 14 external deals. Even Pfizer, despite its $43 billion Seagen acquisition, is sourcing oncology pipeline breadth through external partnerships (Innovent $10.5 billion).
BioCryst’s decision is a more explicit version of the same logic. Rather than maintaining the infrastructure and personnel required for early stage drug discovery—the most expensive and highest failure rate phase of pharmaceutical development—the company will focus its resources on identifying, licensing, and developing rare disease assets that have already demonstrated initial clinical proof of concept. The strategy trades discovery risk for deal execution risk. For a company of BioCryst’s size, concentrating resources on later stage development rather than spreading them across discovery and development may produce better returns.
The Alabama center closure is another data point in the biopharma workforce story. Takeda cut 4,500. Gilead cut 87% of Arcellx. Genentech restructured deep enough to lose a 30 year executive. enGene halved its workforce. BioCryst is closing an entire research center. The industry is not shrinking—total M&A exceeds $134 billion and IPOs have raised $4.1 billion. But the jobs are moving from discovery research to clinical development, commercial operations, and the deal teams that source the external assets that have replaced internal pipelines.
Strategic Themes
1. The Medicare Bridge Shifts the GLP 1 Competition from Scarcity to Access
The first phase was about supply. The second phase is about access. Today is the dividing line. With both Lilly and Novo products covered at $50 per month, the competition shifts from “who can get the drug?” to “which drug is right for which patient?” The three axis framework—efficacy, convenience, access—means the market supports multiple winners. But the enrollment data starting today will determine how large the Medicare GLP 1 population actually is. That number will reshape revenue projections, supply planning, and competitive positioning for the rest of 2026.
2. Three TED Drugs in Two Days Ends a Six Year Monopoly
Tepezza alone since 2020. Lumvoa approved Friday. Enspryng priority review Monday. Two mechanisms (IGF 1R and IL 6). Three companies (Amgen, Viridian, Roche). The speed of competitive entry illustrates what happens when a successful first mover proves a market exists: the followers arrive quickly and in numbers. For patients, more options is unambiguously good. For Amgen, the question is how much share Tepezza can hold against two drugs that each offer a differentiated advantage (shorter course for Lumvoa, different mechanism for Enspryng).
3. Abivax’s Recovery Shows How Binary Biotech Risk Can Be
Down 44% on a cancer signal. Up 40% when the signal fades. The stock moved nearly 85 percentage points in three weeks based on the difference between “the cancer cases are drug related” and “the cancer cases are consistent with the disease.” For investors, the volatility is the price of exposure to clinical stage biotechs with binary outcomes. For the UC market, the recovery puts obefazimod back on track as a potential best in class oral treatment with an NDA due in Q4. The takeover speculation resumes accordingly.
4. BioCryst Closing Its Discovery Center Is the Latest Sign That Pharma Is Outsourcing Innovation
Build versus buy. The industry made its choice in 2026. $134 billion in M&A. Fourteen Lilly deals. Biogen pivoting. BioCryst closing its research center. The economics of internal drug discovery—high cost, high failure rate, long timelines—are driving more companies to source assets externally rather than generate them internally. The discovery talent does not disappear. It migrates to the smaller biotechs and academic labs that become the targets of the licensing deals and acquisitions that the larger companies depend on.
Frequently Asked Questions
What is the Medicare GLP 1 Bridge?
Launches today. Medicare Part D beneficiaries with obesity or overweight with comorbidities can access GLP 1 therapies at $50 per month. Covers Lilly’s Foundayo and Zepbound plus Novo’s oral and injectable Wegovy.
What happened in thyroid eye disease?
Roche received FDA acceptance and priority review for Enspryng (IL 6 receptor antibody) in TED, one business day after Viridian’s Lumvoa (IGF 1R antibody) was approved. Amgen’s Tepezza now faces two competitors through two different mechanisms.
What is the Abivax story?
Obefazimod crashed 44% on a cancer signal in early June. New data showed malignancy rates in line with normal UC patients. Shares recovered 40%. Company on track for Q4 NDA. Widely considered a takeover target at roughly 8 billion euros market cap.
What is the AstraZeneca rare disease data?
Efzimfotase alfa hit Phase 3 in hypophosphatasia, showing improved bone health in treatment naive children with the rare metabolic disease. Strengthens AstraZeneca’s Alexion portfolio.
Why is BioCryst closing its research center?
Shifting from internal drug discovery to externally sourced rare disease assets. Closing its Alabama Discovery Center of Excellence by year end. Reflects the broader industry trend of buying rather than building pipeline assets.
Where does Revolution’s filing stand?
Nearly four weeks post ASCO plenary. CNPV NDA filing still imminent. Truist projects Q3 approval.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The Obesity Market’s Second Phase. We detail the Bridge program structure, model initial enrollment expectations and the data points to watch in the first week, and analyze how the three axis competition (efficacy, convenience, access) plays out between Lilly and Novo in the Medicare population.
TED Goes Competitive. We assess how three drugs across two mechanisms will split a market Amgen built alone, compare the infusion schedules and safety profiles, and model the market share trajectory for Tepezza, Lumvoa, and Enspryng.
Abivax. We analyze why a recovered UC drug is now one of the most watched takeover targets in European biotech, assess which acquirers are most likely to move, and evaluate whether a deal happens before or after the Q4 NDA.
Plus: AstraZeneca Alexion rare disease pipeline, BioCryst discovery exit analysis, Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
